Deep vein thrombosis - Treatment with a selective oestrogen receptor modulator Factor
Last reviewed for CCPS 22 December 2008.
Preliminary questions [25635]
40401 there is some evidence that being treated with a selective oestrogen receptor modulator may be a factor in the development of the condition under consideration.
40402 the veteran has been treated with a selective oestrogen receptor modulator at some time.
25113 the veteran was treated with a selective oestrogen receptor modulator within the 90 days before the clinical onset of the condition under consideration.
the veteran was treated with a selective oestrogen receptor modulator within the 90 days before the clinical onset of the condition under consideration for an illness or injury which is identifiable.26014 — the veteran has established the causal connection between being treated with a selective oestrogen receptor modulator and VEA service for the clinical onset of deep vein thrombosis.
26015 — the veteran has established the causal connection between being treated with a selective oestrogen receptor modulator and operational service for the clinical onset of deep vein thrombosis.
or
26016 — the veteran has established the causal connection between being treated with a selective oestrogen receptor modulator and eligible service for the clinical onset of deep vein thrombosis.
Clinical onset and operational service [26015]
40403 — the identified illness or injury, for which the veteran was being treated with a selective oestrogen receptor modulator, is causally related to operational service.
Clinical onset and eligible service [26016]
40404 — the identified illness or injury, for which the veteran was being treated with a selective oestrogen receptor modulator, is causally related to eligible service.